Long-term clinical effect of the CCLG-ALL2008 regimen in treatment of childhood acute lymphoblastic leukemia with different molecular biological features

CHEN Xiao-Juan; ZOU Yao; LIU Xiao-Ming; YANG Wen-Yu; GUO Ye; RUAN Min; LIU Fang; CHEN Yu-Mei; ZHANG Li; WANG Shu-Chun; ZHU Xiao-Fan

doi:10.7499/j.issn.1008-8830.2019.09.009

PDF(1309 KB)

Chinese Journal of Contemporary Pediatrics ›› 2019, Vol. 21 ›› Issue (9) : 890-893. DOI: 10.7499/j.issn.1008-8830.2019.09.009

CLINICAL RESEARCH

Long-term clinical effect of the CCLG-ALL2008 regimen in treatment of childhood acute lymphoblastic leukemia with different molecular biological features

CHEN Xiao-Juan, ZOU Yao, LIU Xiao-Ming, YANG Wen-Yu, GUO Ye, RUAN Min, LIU Fang, CHEN Yu-Mei, ZHANG Li, WANG Shu-Chun, ZHU Xiao-Fan

Author information +

History +

Abstract

Objective To study the long-term clinical effect of the CCLG-ALL2008 regimen in the treatment of children newly diagnosed with acute lymphoblastic leukemia (ALL) with different molecular biological features. Methods A total of 940 children who were newly diagnosed with ALL were enrolled in this study. The children were treated with the CCLG-ALL2008 regimen. A retrospective analysis was performed for the long-term outcome of ALL children with different molecular biological features. Results Among the 940 children with ALL, there were 570 boys and 370 girls, with a median age of onset of 5 years (range 1-15 years) and a median follow-up time of 65 months (range 3-123 months). The complete response (CR) rate was 96.7%, the predicted 10-year overall survival (OS) rate was 76.5%±1.5%, and the event-free survival (EFS) rate was 62.6%±3.0%. After CR was achieved after treatment, the overall recurrence rate was 21.9%. The children with positive ETV6-RUNX1 had the lowest recurrence rate and were prone to late recurrence, and those with positive MLL rearrangement had the highest recurrence rate and were prone to early recurrence. The children with positive ETV6-RUNX1 had a significantly higher predicted 10-year OS rate than those with positive TCF3-PBX1, BCR-ABL, or MLL rearrangement and those without molecular biological features (P < 0.05). The children with positive ETV6-RUNX1 had a significantly higher predicted 10-year EFS rate than those with positive BCR-ABL or MLL rearrangement (P < 0.05). Conclusions Molecular biological features may affect the long-term prognosis of children with ALL, and positive MLL rearrangement and BCR-ABL fusion gene are indicators of poor prognosis. Children with positive ETV6-RUNX1 fusion gene have the highest long-term survival rate.

Key words

Acute lymphoblastic leukemia / Survival analysis / Molecular biological feature / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

CHEN Xiao-Juan, ZOU Yao, LIU Xiao-Ming, YANG Wen-Yu, GUO Ye, RUAN Min, LIU Fang, CHEN Yu-Mei, ZHANG Li, WANG Shu-Chun, ZHU Xiao-Fan. Long-term clinical effect of the CCLG-ALL2008 regimen in treatment of childhood acute lymphoblastic leukemia with different molecular biological features[J]. Chinese Journal of Contemporary Pediatrics. 2019, 21(9): 890-893 https://doi.org/10.7499/j.issn.1008-8830.2019.09.009

References

[1] Cui L, Li ZG, Chai YH, et al. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008:The first nation-wide prospective multicenter study in China[J]. Am J Hematol, 2018, 93(7):913-920.
[2] 秘营昌, 卞寿庚. 急性淋巴细胞白血病[M]//张之南, 沈悌. 血液病诊断及疗效标准. 第3版. 北京:科学出版社, 2007:116-121.
[3] 中华医学会儿科学分会血液学组, 《中华儿科杂志》编辑委员会. 儿童急性淋巴细胞白血病诊疗建议(第四次修订)[J]. 中华儿科杂志, 2014, 52(9):641-644.
[4] 刘晓明, 邹尧, 王慧君, 等. CCLG-2008方案治疗标危中危儿童急性淋巴细胞白血病中期随访结果[J]. 中华儿科杂志, 2014, 52(6):449-454.
[5] 陈晓娟, 邹尧, 杨文钰, 等. CCLG-ALL2008方案治疗儿童急性淋巴细胞白血病复发患儿的特征分析[J]. 中国当代儿科杂志, 2015, 7(4):321-326.
[6] Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia:progress through collaboration[J]. J Clin Oncol, 2015, 33(27):2938-2948.
[7] Asai D, Imamura T, Yamashita Y, et al. Outcome of TCF3-PBX1 positive pediatric acute lymphoblastic leukemia patients in Japan:a collaborative study of Japan Association of Childhood Leukemia Study (JACLS) and Children's Cancer and Leukemia Study Group (CCLSG)[J]. Cancer Med, 2014, 3(3):623-631.
[8] Pui CH, Mullighan CG, Evans WE, et al. Pediatric acute lymphoblastic leukemia:where are we going and how do we get there?[J]. Blood, 2012, 120(6):1165-1174.
[9] 王邢玮, 李本尚, 沈树红, 等. ETV6/RUNX1阳性儿童急性B系淋巴细胞白血病临床预后研究[J]. 临床儿科杂志, 2016, 34(5):321-325.
[10] 王振华, 戢莉, 王莉红, 等. 伴MLL基因异常白血病的检测及其临床意义[J]. 实用医学杂志, 2018, 34(15):2533-2536.
[11] 郭晔, 刘天峰, 阮敏, 等. 伊马替尼治疗儿童Ph阳性急性淋巴细胞白血病的疗效和安全性[J]. 中国当代儿科杂志, 2015, 17(8):819-824.
[12] Sun C, Chang L, Zhu X. Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse[J]. Oncotarget, 2017, 8(21):35445-35459.
[13] 蔡娇阳, 王宁玲, 蒋慧, 等. 儿童急性淋巴细胞白血病2005方案多中心远期临床报告[J].中华儿科杂志, 2018, 56(7):511-517.
[14] Pui CH, Campana D. Minimal residual disease in pediatric ALL[J]. Oncotarget, 2017, 8(45):78251-78252.
[15] Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia[J]. N Engl J Med, 2009, 360(5):470-480.
[16] Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome:a genome-wide classification study[J]. Lancet Oncol, 2009, 10(2):125-134.
[17] Schmiegelow K, Levinsen MF, Attarbaschi A, et al. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia[J]. J Clin Oncol, 2013, 31(19):2469-2476.
[18] Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia:progress through collaboration[J]. J Clin Oncol, 2015, 33(27):2938-2948.
[19] Pui CH, Pei D, Campana D, et al. A revised definition for cure of childhood acute lymphoblastic leukemia[J]. Leukemia, 2014, 28(12):2336-2343.